Loading...
X11beta rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice.
Mitchell, Jacqueline C Ariff, Belall B Yates, Darran M Lau, Kwok-Fai Perkinton, Michael S Rogelj, Boris Stephenson, John D Miller, Christopher C J McLoughlin, Declan M
Mitchell, Jacqueline C
Ariff, Belall B
Yates, Darran M
Lau, Kwok-Fai
Perkinton, Michael S
Rogelj, Boris
Stephenson, John D
Miller, Christopher C J
McLoughlin, Declan M
Citations
Altmetric:
Advisors
Editors
Other Contributors
Date
2009-12-01
Date Submitted
Keywords
Other Subjects
Subject Mesh
Alzheimer Disease
Amyloid beta-Peptides
Amyloid beta-Protein Precursor
Animals
Behavior, Animal
Carrier Proteins
Disease Models, Animal
Female
Humans
Long-Term Potentiation
Male
Memory
Mice
Mice, Inbred C57BL
Mice, Transgenic
Nerve Tissue Proteins
Amyloid beta-Peptides
Amyloid beta-Protein Precursor
Animals
Behavior, Animal
Carrier Proteins
Disease Models, Animal
Female
Humans
Long-Term Potentiation
Male
Memory
Mice
Mice, Inbred C57BL
Mice, Transgenic
Nerve Tissue Proteins
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
ddp408.pdf
Adobe PDF, 305.91 KB
Alternative Titles
Publisher
Abstract
Increased production and deposition of amyloid beta-protein (Abeta) are believed to be key pathogenic events in Alzheimer's disease. As such, routes for lowering cerebral Abeta levels represent potential therapeutic targets for Alzheimer's disease. X11beta is a neuronal adaptor protein that binds to the intracellular domain of the amyloid precursor protein (APP). Overexpression of X11beta inhibits Abeta production in a number of experimental systems. However, whether these changes to APP processing and Abeta production induced by X11beta overexpression also induce beneficial effects to memory and synaptic plasticity are not known. We report here that X11beta-mediated reduction in cerebral Abeta is associated with normalization of both cognition and in vivo long-term potentiation in aged APPswe Tg2576 transgenic mice that model the amyloid pathology of Alzheimer's disease. Overexpression of X11beta itself has no detectable adverse effects upon mouse behaviour. These findings support the notion that modulation of X11beta function represents a therapeutic target for Abeta-mediated neuronal dysfunction in Alzheimer's disease.
Language
en
ISSN
1460-2083
eISSN
ISBN
DOI
10.1093/hmg/ddp408
PMID
19744962